29 Apr, 2021
\n \n \n \nRecognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.
\n \n\n \n \n16 Apr, 2021
\n \n \n \nOxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.
\n \n\n \n \n8 Apr, 2021
\n \n \n \nThree NDORMS researchers have received awards from the International Dupuytren Society, a patient organisation that brings together Dupuytren Disease patient societies from across the world.
\n \n\n \n \n11 Mar, 2021
\n \n \n \nNew research published in The Lancet shows that tocilizumab is a more effective treatment than rituximab for rheumatoid arthritis patients with a poor response to anti-tumour necrosis factor (TNF).
\n \n\n \n \n8 Mar, 2021
\n \n \n \nThe research, which was a collaboration with researchers from Oxford University and Queen Mary University of London and published in Journal of Autoimmunity, looked at changes in receptors known as toll-like receptors (TLRs) in arthritis at different stages of disease.
\n \n\n \n \n4 Feb, 2021
\n \n \n \nNew Research from the Kusumbe group at the Kennedy Institute of Rheumatology identifies vascular attrition, marked by pericyte to fibroblast differentiation, as a primary hallmark of aging and highlights organ-specific vascular changes with age.
\n \n\n \n \n15 Jan, 2021
\n \n \n \nThe Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.
\n \n\n \n \n18 Dec, 2020
\n \n \n \nA preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults
\n \n\n \n \n18 Dec, 2020
\n \n \n \nIn a combined effort to help COVID-19 researchers the University of Oxford and Cardiff University have launched a series of \u201cliving reviews\u201d in Oxford University Press\u2019s new open access journal \u201cOxford Open Immunology\u201d.
\n \n\n \n \n18 Dec, 2020
\n \n \n \nOxford University has today been awarded a \u00a32.4 million grant, as part of the Kennedy Trust MB PhD scheme, to fund undergraduate medical students to undertake DPhil research in the areas of inflammation, immunology and musculoskeletal disease.
\n \n\n \n \n11 Dec, 2020
\n \n \n \nNew research from the Kusumbe Group at the Kennedy Institute has shown a direct correlation between age-related decline in capillary and artery numbers and hormone production in the endocrine system.
\n \n\n \n \n10 Dec, 2020
\n \n \n \nFive new Oxford-Bristol Myers Squibb Fellowships representing an investment of \u00a33M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
\n \n\n \n \n25 Nov, 2020
\n \n \n \nPeople with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
\n \n\n \n \n13 Nov, 2020
\n \n \n \nProfessor Simon has been successful in her Wellcome Trust Investigator Award entitled: \u201cProteostasis and Autophagy in Immune Senescence.\u201d
\n \n\n \n \n3 Nov, 2020
\n \n \n \nNDORMS has been designated a EULAR Centre of Excellence 2020-2025, in recognition of our continued high-quality research publications in rheumatology.
\n \n\n \n \n30 Oct, 2020
\n \n \n \nIn a collaboration with scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Kennedy researchers have contributed to the discovery that neutrophils have many more functions in the body than previously thought. This finding suggests that neutrophil tissue-specific plasticity could be exploited in designing new treatments for neutrophil driven diseases, including cancer.
\n \n\n \n \n23 Oct, 2020
\n \n \n \nProfessor Marco Fritzsche has joined the Kennedy Institute as the Principal Investigator of the Biophysical Immunology Laboratory (BPI), as part of a joint appointment with the Rosalind Franklin Institute. His lab is leading the development of a lattice light sheet microscope that will significantly advance the study of live cells.
\n \n\n \n \n20 Oct, 2020
\n \n \n \nA team from the University of Oxford has visualised how key cells of the immune system lock onto cancerous or infected cells to destroy them. The work was led by the Mike Dustin\u2019s group at the Kennedy Institute of Rheumatology and experts in colorectal and ovarian cancers from across Oxford and computational biologists at the University of Birmingham.
\n \n\n \n \n19 Oct, 2020
\n \n \n \nNDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.
\n \n\n \n \n2 Oct, 2020
\n \n \n \nResearchers at the Kennedy Institute review the growing body of literature on the role of the microbiome in colorectal cancer
\n \n\n \n \n